Genextra

InnovHeart is a medical equipment manufacturing company that specializes in developing transcatheter mitral valve replacement systems. The company aims to provide a novel therapeutic solution for patients with mitral valve disease by offering an innovative implant technology designed for replacing incompetent mitral valves. This technology is characterized by its safety, effectiveness, and ease of use, enabling hospitals to treat patients suffering from heart valve dysfunction more efficiently.

InnovHeart is a medical equipment manufacturing company that specializes in developing transcatheter mitral valve replacement systems. The company aims to provide a novel therapeutic solution for patients with mitral valve disease by offering an innovative implant technology designed for replacing incompetent mitral valves. This technology is characterized by its safety, effectiveness, and ease of use, enabling hospitals to treat patients suffering from heart valve dysfunction more efficiently.

EryDel, based in Urbino, has developed a patented technology for drug delivery utilizing erythrocytes, or red blood cells. This innovative approach enables the efficient loading of red blood cells with various therapeutic agents, including drugs, proteins, and nanoparticles, which can be gradually released into the patient's body. The technology enhances treatment efficacy while minimizing side effects, particularly for chronic conditions that typically require daily medication. EryDel's solution has undergone testing in patients suffering from Inflammatory Bowel Diseases such as ulcerative colitis and Crohn's disease. Additionally, the company provides comprehensive support for the drug delivery process through its specialized device, the "Red Cell Loader," and associated disposable kits. This system aims to streamline blood processing at the point of care, enabling healthcare professionals to deliver therapies for a range of conditions efficiently.

EryDel, based in Urbino, has developed a patented technology for drug delivery utilizing erythrocytes, or red blood cells. This innovative approach enables the efficient loading of red blood cells with various therapeutic agents, including drugs, proteins, and nanoparticles, which can be gradually released into the patient's body. The technology enhances treatment efficacy while minimizing side effects, particularly for chronic conditions that typically require daily medication. EryDel's solution has undergone testing in patients suffering from Inflammatory Bowel Diseases such as ulcerative colitis and Crohn's disease. Additionally, the company provides comprehensive support for the drug delivery process through its specialized device, the "Red Cell Loader," and associated disposable kits. This system aims to streamline blood processing at the point of care, enabling healthcare professionals to deliver therapies for a range of conditions efficiently.

Intercept Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the development and commercialization of therapeutics for progressive non-viral liver diseases. Based in New York, the company’s lead product is Ocaliva, an agonist of the farnesoid X receptor, approved for the treatment of primary biliary cholangitis in adults. Intercept is actively exploring additional indications for Ocaliva, including nonalcoholic steatohepatitis. Furthermore, the company is engaged in the research and development of other drug candidates aimed at addressing chronic liver diseases and metabolic disorders. Intercept has established partnerships for the development and commercialization of its products in specific regions, including agreements with Sumitomo Dainippon Pharma for the Asian markets and Aralez Pharmaceuticals for bezafibrate in the United States. The company employs a multifaceted approach to marketing its products, utilizing an internal commercial organization as well as third-party distributors. Founded in 2002, Intercept Pharmaceuticals continues to advance its mission to address unmet medical needs in liver disease.

Intercept Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the development and commercialization of therapeutics for progressive non-viral liver diseases. Based in New York, the company’s lead product is Ocaliva, an agonist of the farnesoid X receptor, approved for the treatment of primary biliary cholangitis in adults. Intercept is actively exploring additional indications for Ocaliva, including nonalcoholic steatohepatitis. Furthermore, the company is engaged in the research and development of other drug candidates aimed at addressing chronic liver diseases and metabolic disorders. Intercept has established partnerships for the development and commercialization of its products in specific regions, including agreements with Sumitomo Dainippon Pharma for the Asian markets and Aralez Pharmaceuticals for bezafibrate in the United States. The company employs a multifaceted approach to marketing its products, utilizing an internal commercial organization as well as third-party distributors. Founded in 2002, Intercept Pharmaceuticals continues to advance its mission to address unmet medical needs in liver disease.

Intercept Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the development and commercialization of therapeutics for progressive non-viral liver diseases. Based in New York, the company’s lead product is Ocaliva, an agonist of the farnesoid X receptor, approved for the treatment of primary biliary cholangitis in adults. Intercept is actively exploring additional indications for Ocaliva, including nonalcoholic steatohepatitis. Furthermore, the company is engaged in the research and development of other drug candidates aimed at addressing chronic liver diseases and metabolic disorders. Intercept has established partnerships for the development and commercialization of its products in specific regions, including agreements with Sumitomo Dainippon Pharma for the Asian markets and Aralez Pharmaceuticals for bezafibrate in the United States. The company employs a multifaceted approach to marketing its products, utilizing an internal commercial organization as well as third-party distributors. Founded in 2002, Intercept Pharmaceuticals continues to advance its mission to address unmet medical needs in liver disease.

Intercept Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the development and commercialization of therapeutics for progressive non-viral liver diseases. Based in New York, the company’s lead product is Ocaliva, an agonist of the farnesoid X receptor, approved for the treatment of primary biliary cholangitis in adults. Intercept is actively exploring additional indications for Ocaliva, including nonalcoholic steatohepatitis. Furthermore, the company is engaged in the research and development of other drug candidates aimed at addressing chronic liver diseases and metabolic disorders. Intercept has established partnerships for the development and commercialization of its products in specific regions, including agreements with Sumitomo Dainippon Pharma for the Asian markets and Aralez Pharmaceuticals for bezafibrate in the United States. The company employs a multifaceted approach to marketing its products, utilizing an internal commercial organization as well as third-party distributors. Founded in 2002, Intercept Pharmaceuticals continues to advance its mission to address unmet medical needs in liver disease.